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Abstract 
The abundance of Th2 cells in both the airways and circulation associates with asthma 
severity. Activation of CRTh2 expressed by Th2 cells mediates production of Th2 cytokines 
and inhibits apoptosis. Glucocorticosteroid effects occur through suppression of Th2 
cytokines and induction of apoptosis. However, recent evidence shows that the total daily 
dose of inhaled glucocorticosteroids was positively correlated with the percentage of 
circulating Th2 cells. As such, we chose to examine regulation of Th2 cells by 
glucocorticosteroids. We used CCRF-CEM cells as a Th2 cell model and in vitro 
differentiated primary Th2 cells to study the effect of dexamethasone. Low dose 
dexamethasone treatment reduced IL-13 but surprisingly increased CRTh2, while only high 
dose induced apoptosis. Interestingly, T cell activation reduced glucocorticosteroid receptor 
signaling genes FKBP5 and GR transcript levels. Our results suggest that 
glucocorticosteroids at insufficient doses to trigger apoptosis may sustain CRTh2+ Th2 cells 
and thereby maintain inflammation.  
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Chapter 1 : Introduction 
1 Overview 
Asthma is a chronic inflammatory disease of the airways that affects over 3 million 
Canadians (8% of the population) over the age of 12 [1]. Asthma is a growing problem as it 
is expected to affect  over 100 million people worldwide by the year 2025 [1]. Although most 
types of asthma are well controlled by medication, asthma has an annual cost to our 
healthcare system of 600 million dollars [1]. The majority of the asthma related healthcare 
costs occur from patients suffering from severe difficult-to-treat asthma [2]. The 
pathogenesis of severe forms of asthma is considered largely related to type 2 inflammation. 
The inflammation in asthma patients influences response to glucocorticosteroid (GC), the 
main anti-inflammatory medication for asthma [2]. Indeed, much research has examined the 
question of why severe asthmatics exhibit persistent inflammation and overall poor control of 
their disease despite taking the highest doses of GC [2]. As such, this study focused on 
understanding how GCs influence Th2 cells, a T lymphocyte subset elevated in severe 
asthma [3, 4].  
1.1 Asthma  
Asthma patients present clinically with symptoms such as wheezing, shortness of breath, and 
chest tightness [5]. Diagnosis of asthma is based primarily on symptoms and reversible 
airflow obstruction [5]. Asthma diagnosis can be determined by objective measures such as 
forced expiratory volume in one second (FEV1) [6].  A spirometer is commonly used to 
assess lung function by measuring changes in the volume of air inhaled and exhaled [5, 6].  
Asthma is classified as an obstructive lung disease due to the narrowing of the airways [5]. 
Thus, asthma patients often have difficulty exhaling air at a normal rate. FEV1 assesses lung 
function by determining the maximum volume of air exhaled in one second [6]. FEV1 values 
are represented as percent predicted, which compares measured FEV1 values relative to 
expected FEV1 based on height, sex, race and age [6]. An FEV1 of 80% of the percent 
predicted is considered normal [5, 6]. Asthma diagnosis requires performing FEV1 before 
and after administration of a bronchodilator and increases of FEV1 by 15% and/or 200 mL 
identify reversible airflow obstruction [6, 7]. In this circumstance, reversibility of airflow 
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obstruction is used to diagnose asthma over the other major chronic disease of the airways, 
chronic obstructive pulmonary disease (COPD) which does not show airway reversibility [8]. 
Another method used to assess variable airflow obstruction is through administration of a 
bronchial constrictor [2]. Airway hyper responsiveness (AHR) in asthma is characteristic of 
inflammation and smooth muscle cell abnormalities in the airways [9]. Bronchiole 
provocation tests (BPTs) are used clinically to assess AHR [9]. Adenosine 5’-
monophosphates (AMPs) that bind A2B receptors to induce degranulation of mast cells are 
used as an indirect BPT [9, 10]. Mast cells release inflammatory mediators such as 
histamines, leukotrienes and prostaglandins that act on smooth muscle cells leading to 
bronchoconstriction [11]. Thus, AMPs test inflammatory regulation of AHR which is an 
indirect measure. Enhanced sensitivity of muscarinic receptors on smooth muscle cells lining 
the airways contributes to AHR [12]. The methacholine challenge is a type of direct BPT that 
utilizes methacholine which binds muscarinic receptors and induces bronchial constriction 
[13]. Thus, asthma patients with enhanced muscarinic receptor sensitivity have bronchioles 
that constrict at low doses of methacholine [2]. The concentration that causes FEV1 to drop 
by 20% is considered the provocation concentration (PC20) [2, 7]. Normal airways would 
have a PC20 of > 16 mg/ml and an asthmatic patient would have a PC20 of < 8mg/ml [2].  
Measuring lung function and reversibility reflects the effect of the inflammatory process but 
does not indicate the type of inflammation. The airway inflammation in asthma patients 
determines a patients’ response to treatment.  
1.1.1 Treatment 
Strategies for asthma treatment focus on temporary relief of symptoms and reduction of 
chronic inflammation. Inhaled GCs are the mainstay for asthma treatment due to their ability 
to reduce airway inflammation [14]. Oral GCs are prescribed in the cases of more severe 
forms of asthma despite the high risk for adverse side effects such as osteoporosis, high 
blood pressure and obesity with long-term use. Treatment strategies for asthma patients often 
involve combinatorial therapy which involve controller medication such as GCs to reduce 
inflammation and a reliever medication for temporary relief of symptoms [15]. Reliever 
medications include short-acting bronchodilators, such as those that act on β2-adrenergic 
receptors on smooth muscle cells that alleviate bronchial constriction [16]. Cysteinyl 
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leukotriene (CysLT) receptor antagonists are another family of controller drugs used to target 
inflammation mediated symptoms [15]. CysLTs are strong contractile agonists released by 
mast cells that are increased in active asthma, thus antagonist treatment blocks potential 
bronchoconstriction, edema and mucous production [17]. Advances in our understanding of 
asthma have allowed for development of therapeutics with specific immunological targets 
[15]. For example, Omalizumab an anti-IgE medication has shown to be successful as an add 
on therapy in patients with IgE mediated asthma [18].   
1.1.2 Severity 
One of the main ways to categorize asthma is based on severity, which is determined based 
on symptoms, lung function and response to asthma therapy [2]. The American Thoracic 
Society (ATS) defines mild asthma as having symptoms at least 2 times a week but normal 
FEV1 (≥ 80%) and requiring no or only low dose inhaled GCs [2, 19]. Moderate asthma is 
when patients have daily symptoms accompanied by reduced lung function (FEV1 between 
60-80%), but are taking < 800 µg of inhaled beclomethasone to control their symptoms [2, 
19]. Severe asthmatics, on the other hand, have an FEV1 below the normal limit at < 80% 
along with persistent symptoms despite taking > 800 µg of beclomethasone a day, and the 
need for other controller medications and/or oral GCs [2, 19].  
1.1.3 Inflammation 
Although clinically asthma is categorized as mild/moderate/severe, these subgroups are not 
well associated with a particular type of inflammation [20]. For instance, asthma has been 
divided into phenotypes based on the predominance of inflammatory cells such as 
eosinophils, helper T cells and neutrophils [21]. The underlying pathology of asthma is 
further diversified by etiology [22]. The most common classifications are known as non-
allergic and allergic asthma [22, 23]. Non-allergic asthma occurs in the absence of an allergic 
reaction and is considered to be due to viral infections, exercise or other primary diseases that 
influence bronchial obstruction [23]. Non-allergic asthma is often associated with 
neutrophilic and Type 1 cytokine related inflammation [23, 24]. Allergic asthma is defined 
by a hypersensitive reaction that occurs in response to an allergen [23, 25] and is commonly 
associated with T helper 2 cells (Th2) and eosinophils [23, 26]. Th2 high asthmatic patients 
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have been associated with severe asthma [21]. As research continues to uncover the diversity 
of asthma this will advance our understanding of its etiology, pathology and treatment [27].  
1.2 Development of Allergic Asthma   
Allergic asthma is the most common type of asthma and is characterized by elevated blood 
and airway eosinophilia and Th2 inflammation [28-30]. It often develops during childhood 
following sensitization to an allergen(s) [20]. Both genetic and environmental factors that 
influence the developing immune system have been associated with becoming sensitized and 
developing allergic asthma [31]. 
1.2.1 Atopy 
Individuals that are genetically predisposed to developing allergic diseases usually become 
atopic early in life [32]. Atopy, the state of being sensitized to an antigen, is assessed by a 
positive skin prick test or measuring total serum IgE levels [33]. Exposure to LPS from living 
on a farm during the first year of life was shown to protect against sensitization, while 
environmental pollution has been associated with increased risk of developing asthma [34, 
35].  
1.2.2 Epithelium  
Allergen sensitization develops as a result of an innocuous environmental antigen known as 
an allergen activating both the innate and adaptive immune system. The cells of the innate 
immune system act as the first line of defense against antigens. In the case of allergic asthma, 
the epithelium lining the airways is the first line of contact and its activation initiates an 
immune response [36]. The epithelial cells express pattern recognition receptors that are 
activated upon allergen exposure to promote allergen sensitization and Th2 mediated 
inflammation [37]. Mutations in proteins regulating epithelial integrity such as E-cadherin, α-
catenin and ZO-1 have been associated with enhanced allergic sensitization [38]. Loss of 
epithelial integrity by epithelial remodeling also makes asthmatics more sensitive to allergen 
re-exposure over-time [39]. Even in the absence of any primary epithelial dysfunction, 
allergens such as house dust mites (HDM) can cleave tight junctions connecting epithelial 
cells to enter the lung mucosal layer [40].  
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1.2.3 Antigen Presentation 
Antigens in the lung mucosa are recognized by antigen presenting cells (APCs), the cells 
which provide the crucial link between the innate and adaptive immune system [41]. The 
epithelium secretes factors such as interleukin-33 (IL-33), thymic stromal lymphopoietin 
(TSLP) and interleukin-25 (IL-25) that promote maturation of APCs in response to allergen 
exposure [37]. APCs such as dendritic cells, macrophages and B cells take up antigens and 
process them for presentation to CD4+ T cells [42]. Dendritic cells are the main APCs 
responsible for sensitization in allergic asthma [43, 44]. Through phagocytosis or receptor 
mediated endocytosis APCs take up the allergen and process a peptide from the allergen 
(antigen) into a complex with major histocompatibility complex (MHC) class Ⅱ molecules on 
the surface [42]. These APCs migrate to the lymph nodes and present antigens to naive CD4+ 
T cells [42].  
1.2.4 IgE Production 
Interaction of APCs with naïve CD4+ helper T cells (Th) mediates T cell differentiation into 
multiple subtypes including Th1, Th2, Th17, induced regulatory T cells (iTreg) and follicular 
helper T cells (Tfh) [45].  For many years, Th2 cells were thought to be the primary cells 
interacting with B cells to induce isotype switching to IgE [46, 47]. More recently, however, 
it has been shown that dendritic cell activated CD4+ T cells first differentiate into Tfh cells 
[48]. Tfh cells express Th2 cytokines (IL-4 and/or IL-13) required to induce B cells to form 
specialized B cells called plasma cells to produce IgE [49]. Plasma cells migrate to the site of 
allergen exposure and produce IgE, which binds to fragment crystallizable Epsilon Receptor 
1 (FcɛR1) present on mast cells [50]. This binding of IgE to mast cell represents allergen 
sensitization, where an individual is primed to respond to subsequent exposure to allergen. 
1.2.5 Th2 Cell Differentiation 
Helper T cell differentiation depends on factors such as type of antigen, level of antigen 
stimulation, and cytokine environment [45]. Moderate T cell receptor (TCR) cross-linking 
favors differentiation to Th2 cells versus high level stimulation, which favors Th1 cell 
development [45]. Dendritic cells stimulate naïve CD4+ T cells to differentiate into Th2 cells 
through CD3/CD28 crosslinking/co-stimulation, which induces IL-2 and low level IL-4 
production from differentiating T cells[51-53]. IL-4 binds to the IL-4R, activating  the 
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transcription factor STAT6, which leads to more IL-4 production through autocrine 
regulation which promotes Th2 cell differentiation [54]. GATA3 is also upregulated 
following TCR activation and both STAT6 and GATA3 remodel the chromatin to open 
enhancer regions within genes that enable maintenance of the Th2 phenotype [55]. Despite 
this low level of IL-4 production, an external source of IL-4 is likely required to promote full 
Th2 differentiation alongside TCR activation, which has been suggested to be basophils 
and/or lung tissue residing type 2 innate lymphoid like cells (ILC2s) [56, 57]. A recent study 
has suggested that the major source of Th2 cells is not through direct differentiation from 
CD4+ T cells but from development of precursor Tfh cells [58]. Dendritic cells and B cells 
are required for the development of IL-4 producing Tfh cells [58]. With exposure to HDMs 
Tfh cells sustain plasticity to differentiate into type 2 effector helper T cells that can act as 
precursors for pathogenic Th2 cells [58]. Inhibiting the production of Tfh cells reduced the 
abundance of Th2 cells residing in the lung following HDM exposure [58]. Thus, it appears 
that although CD4+ T cells can differentiate into Th2 cells, parallel production from 
precursor type 2 Tfh cells is also a source of Th2 cells [48, 58].  
1.2.6 Other Avenues to Allergic Sensitization 
Though allergic sensitization has been largely considered to be the main driver of type 2 
inflammation, recently factors other than allergens have been shown to induce expression of 
these cytokines. The epithelium has been shown to produce IL-25 and IL-33 not only in 
response to allergen, but also following exposure to virus and pollutants such as cigarette 
smoke [59-61]. IL-25 can bind to the IL-25 receptor on naïve T cells to promote Th2 
differentiation and induce IL-5 and IL-13 expression [62, 63]. Similarly, IL-33 has been 
shown to stimulate basophils to secrete IL-4 and ILC2s to secrete IL-13 and IL-5 [64]. The 
IL-4 production by basophils is thought to serve as a source of IL-4 initiating Th2 
differentiation [56, 65]. ILC2 secretion of IL-13 has been shown to promote dendritic cell 
migration to lymph nodes to promote Th2 differentiation [65]. As such, there is now an 
appreciation for the fact that ‘type 2 inflammation’ can develop from allergic sensitization or 
following microbial exposures which creates a cytokine milieu that could support subsequent 
allergic sensitization. 
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1.2.7 Developing Chronic Inflammation 
Once an individual is sensitized, reintroduction of the allergen initiates a type 1 
hypersensitivity reaction [50]. The early phase of this response is elicited by mast cell 
degranulated induced by allergen binding IgE. Mast cell degranulation releases histamines, 
chemokines and the lipid mediator prostaglandin D2 (PGD2), which resolves within the 30 
minutes [50, 66]. The late phase response, 6 - 24 hours following exposure, is mediated by 
inflammatory cell infiltration and amplification of type 2 cytokine expression [67]. During 
this response memory T cells develop from re-stimulation by antigens [44]. 
Four main types of memory T cells develop, stem (TSM), central (TCM), effector (TEM) and 
resident memory T cells (TRM) [68]. TSM cells were recently identified in humans as memory 
T cells that express FAS, CD122 and naïve markers such as CD45RA [69]. TSM cells have 
high proliferative capacity and can differentiate into TCM or TEM cells upon re-stimulation by 
antigens [69].  TCM cells have minimal effector function and in response to antigen 
stimulation proliferate and differentiate to produce TEM [68]. TEM express CCR4 receptors 
required to infiltrate into lung tissue from circulation, while TCM express CD62L, CCR7 and 
CD27, which mediate emigration out of tissues and migration back to secondary lymphoid 
organs [67, 68]. TCM cells differentiation into TEM cells require the loss of CCR7 expression 
to prevent migration into lymph nodes [67]. TEM cells can differentiate into TRM cells that 
reside in tissue [70]. TRM cells derived from CD4+ T cells have been shown to secrete IL-2, 
tumour necrosis factor α (TNFα) and interferon gamma (IFNγ) in the lungs [71]. Memory T 
cells are detrimental for chronic inflammation as re-stimulation causes a much more rapid 
and effective response than non-memory T cells, thus for this reason these cells have been 
targets for immunotherapy [72].   
1.2.8 Type 2 Cytokines 
If exposure is continual, inflammation can become chronic with persistent infiltration of 
eosinophils and Th2 cells with the secretion of type 2 cytokines IL-4, IL-5 and IL-13 [26]. 
Each of these cytokines plays an important role in type 2 inflammation. In addition to the 
initiation, maintenance and proliferation of Th2 cells, both IL-4 and IL-13 activate the 
endothelium to mediate inflammatory cell infiltration [51, 54, 73, 74]. IL-13 also stimulates 
epithelial cells to express the MUC5AC gene and produce mucous and smooth muscle cells 
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to enhance contractility through elevated calcium signaling [75, 76]. IL-5 regulates 
eosinophils [77], stimulating their production in the bone marrow and migration from the 
bone marrow to the site of allergen exposure through binding of the IL-5 receptor [78, 79]. 
Overall IL-4, IL-5 and IL-13 play significant roles in the inflammatory process leading to 
narrowing of the airways of asthmatic patients. 
1.3 Chemokine Receptor Homologous Molecule Expressed on Th2 
cells (CRTh2) is a marker for Th2 cells 
In a subtractive RNA hybridization screen of Th2 vs Th1 human cells, Nagata et al showed 
the differential expression of a transcript called G protein coupled receptor 44 [80]. Since this 
gene has homology with chemokine receptors, they called it chemokine receptor homologous 
molecule expressed on Th2 cells (CRTh2) [81]. Their characterization of the receptor 
showed surface expression of CRTh2 on Th2, but not Th1 cells, and that CRTh2+ CD4+ T 
cells were those that produced IL-4, IL-5 and IL-13 in response to allergen challenge [80, 
82]. Despite its name, CRTh2 is also expressed by eosinophils, basophils, ILC2s and was 
reported to be present within mast cells [83-85]. However, a subsequent study revealed that 
within the CD4+ T helper cell subset, CRTh2 was the most reliable marker of cells 
expressing the Th2 cytokine profile [86]. 
1.3.1 CRTh2+ Th2 cells are elevated in allergic disease 
CRTh2+ Th2 cells are increased in patients with atopic dermatitis, nasal mucosa of patients 
with allergic rhinitis and the lungs of patients with asthma [4, 87, 88]. Not only are Th2 cells 
elevated within the sites of exposure, but also in the circulation of patients with allergic 
airway disease [3, 44]. Single nucleotide polymorphisms (SNPs) in CRTh2 have been 
associated with higher susceptibility to develop phenotypes of allergic disease, including 
allergic asthma, further supporting the importance of CRTh2 in the development of allergic 
inflammatory diseases [89-91]. 
1.3.2 CRTh2+ Th2 cells are central memory T cells 
Wang et al identified that Th2 cells are central memory T cells that are sustained in 
circulation and form memory against allergens [44]. Memory Th2 cells have been identified 
as dominant inflammatory cells involved in the pathogenesis of allergic asthma [44]. The 
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majority of memory Th2 cells are at resting state and upon activation form effector memory 
cells [68]. Research has identified various pathogenic subsets of memory Th2 cells that 
enhance inflammation through secretion of type 2 and non-type 2 cytokines. For example, 
IL-5+ memory CRTh2+ Th2 cells have been correlated with blood eosinophils and shown to 
regulate AHR [92]. IL-17 producing Th17 cells that are marked by CCR6 expression have 
been implicated in steroid resistance, thus may be involved in difficult to treat severe asthma 
[93]. CCR6+ CRTh2+ Th2 cells produce both IL-17 and IL-4 and were associated with 
recruitment of neutrophils, macrophages, eosinophils at levels superior to Th2 or Th17 cells 
independently [94]. The maintenance of memory cells in-vivo provides a challenge in 
eliminating inflammation through the reduction of just cytokines and other inflammatory 
proteins. While immune memory is beneficial for pathogen elimination, in the case of 
allergic disease long lived central memory Th2 cells are one of the main factors mediating 
persistence of disease.  
1.4 Functions of the CRTh2 Signaling Pathway 
CRTh2 is a G-protein coupled receptor (GPCR) that uses Gαi proteins and therefore inhibits 
adenylyl cyclase activity [95]. The ligand for CRTh2 is PGD2, released by mast cells 
following allergen-IgE crosslinking and is also considered the second D prostanoid receptor 
(DP2) [96, 97]. To date, activation of CRTh2 has been shown to regulate Th2 cells by three 
main ways, secretion of cytokines, chemotaxis and inhibition of apoptosis (Figure 1) [95, 98, 
99].  
1.4.1 CRTh2 Mediates Th2 Cytokine Production 
In vitro culture of Th2 cells with PGD2, showed that CRTh2 activation results in secretion of 
type 2 inflammatory cytokines IL-4, IL-5 and IL-13, but not IL-10 [99]. The mechanism has 
been shown to be through Nuclear factor of activated T cells (NFAT) signaling [100]. In 
vivo, mice deficient in CRTh2, either through gene knockout (CRTh2-/-) or using CRTh2 
antagonists had reduced production of type 2 cytokines in response to allergen sensitization 
and challenge [101, 102]. Also, overexpression of lipocalin PGD synthase in mice, the 
enzyme responsible for PGD2 production, mediated  increase in type 2 cytokines in the 
bronchoalveolar lavage (BAL) [103]. CRTh2 mediated release of cytokines is considered to 
be through PI3K activation and calcium mobilization [100]. Calcium mobilization in 
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response to CRTh2 activation induces calcineurin activity, which dephosphorylates NFAT 
allowing for nuclear import leading to transcription of IL-4, IL-5 and IL-13 [100]. The 
PGD2-CRTh2 activation of PI3K also activates AKT, which in turn phosphorylates and 
inhibits GSK3β [100]. GSK3β can inhibit NFAT through phosphorylation to inhibit NFATs 
ability to bind DNA and induce transcription [104].  
1.4.2 CRTh2 Mediates Th2 Cell Chemotaxis  
CRTh2 also induces Th2 cell chemotaxis by PGD2-mediated PI3K signaling pathway [95]. 
Overexpression of lipocalin PGD synthase in mice showed increased inflammatory cells in 
BAL after allergen challenge [103]. AKT phosphorylation leads to F-actin polymerization 
which induces chemotaxis in Th2 cells [100]. This mechanism of PGD2 mediated chemotaxis 
has also been shown in eosinophils and basophils [95]. Interestingly, though, inhibition of 
AKT in Th2 cells showed only partial inhibition of chemotaxis. ERK activation may be a 
partial regulator of chemotaxis as ERK facilitates CRTh2 mediated chemotaxis of 
eosinophils [100, 105].   
1.4.3 CRTh2 Inhibits Apoptosis in Th2 cells   
PGD2-CRTh2 activation has been shown to inhibit apoptosis in response to IL-2 starvation 
and therefore CRTh2 appears to regulate survival [98]. CRTh2 is a GPCR utilizing Gαi 
protein, so activation results in influx of Ca2+ from cellular calcium stores [95]. This calcium 
influx has been shown to activate PI3K, phosphorylation of AKT and BCL-2 associated 
death promotor protein (BAD), which interferes with anti-apoptotic proteins BCL-2 and 
BCL-xL [98]. Interference of BCL-2 and BCL-xL would initiate caspase-3 mediated 
apoptosis, but AKT signaling downstream of CRTh2 activation inhibits this pathway [98]. 
Xue et al showed that increasing amounts of PGD2 reduced percentage of Annexin V+ Th2 
cells induced by IL-2 starvation [98]. Annexin V staining is an assay for detecting viable 
cells undergoing early apoptosis through binding of phosphytidylserines (PS) [106]. During 
initiation of apoptosis XRP8 lipid scramblase disrupts the membrane and causes PS to flip 
from inner membrane leaflet to outer membrane leaflet [107]. PS can be bound by calcium 
dependent protein Annexin V which in combination with nuclear dye 7AAD or propidium 
iodide is used to assess early apoptosis and cell death, respectively [106].  
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Chronic airway inflammation is initiated by allergen surpassing the epithelial barrier and 
binding to IgE present on mast cells to cause mast cell degranulation release of PGD2 (1). 
PGD2 binds to inflammatory cells in circulation leading to chemotaxis of these cells into the 
lung mucosal layer (2). Th2 cells recruited into the lung mucosa and ILC2s can bind CRTh2 
and release type 2 cytokines to enhance inflammation (3). This process occurs chronically 
leading to narrowing of the airways.     
1.5 Glucocorticosteroid Mechanisms of Action  
Since its introduction in 1950, treatment with synthetic GCs has been the main method of 
reducing chronic inflammation in asthma [108]. Oral GCs have a broad range of effects on 
various tissues leading to obesity, osteoporosis and hypertension which led to the 
development of inhaled GCs [108]. Inhaled GCs reduce inflammation in the airways with 
minimal systemic absorption. Continued development of more effective inhaled GCs aims to 
enhance receptor potency while minimizing off-site systemic effects [108, 109]. Ultimately, 
the best approach would be a treatment with no/low side effects and long-lasting effects. 
GCs function through binding the GC receptor (GR), which resides in the cytoplasm in a 
heterocomplex that includes the chaperone proteins Heat Shock Protein 90 (HSP90) and 
FK506 Binding Protein 5 (FKBP5) [110]. Binding of GCs to GR results in a conformational 
change and FKBP5 losing affinity for the GR [110]. At this time, FKBP4 then replaces 
FKBP5 in the heterocomplex and interacts with dynein motor proteins to transport the GR 
Figure 1: CRTh2 mediated chronic inflammation 
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into the nucleus [110, 111]. The ability of GCs to reduce inflammation is mediated through 
many mechanisms including binding directly to DNA, affecting mRNA stability and protein-
protein interactions (Figure 2) [14].  
1.5.1 Glucocorticosteroid Mediated Transcriptional Regulation 
The GR enters the nucleus and dimerizes with itself or other transcription factors to regulate 
gene transcription [112]. GR homodimers bind to positive and negative glucocorticoid 
response elements (GREs), to activate and repress transcription, respectively [113]. 
Interestingly, the GR can upregulate expression of proteins involved in the GR signaling 
pathway such as GR and FKBP5 [114, 115]. GR represses transcription of pro-inflammatory 
genes such as JUN, IL-11 and MAP3K14 [113]. The GR can also activate transcription of 
anti-inflammatory genes such as MKP-1, IκB, and GILZ [113, 116, 117]. One of the benefits 
of combination therapy with GCs and β agonists is due to the ability of GR to increase 
transcription of β2 adrenergic receptor which is reduced in SMCs lining the airways of 
asthmatics [118]. Typically, the GR is thought to increase anti-inflammatory gene 
transcription and reduce pro-inflammatory gene transcription. However, GCs are also known 
to play a key role in T cell maturation and differentiation of Tregs through transcriptional up-
regulation of FOXP3 and glucocorticosteroid induced tumor necrosis factor receptor (GITR) 
[119].  
Generally, GCs are thought to negatively regulate cytokine expression. Naïve T cells treated 
with GCs and CD3 showed a reduction in IL-4 expression [120].  GC treatment in patients 
with allergic diseases reduced mRNA expression of type 2 cytokines IL-4, IL-5 and IL-13 
[121-124]. The reduction of IL-5 by GCs also reduced eosinophil recruitment [122]. TSLP 
contains negative GREs that the GR binds to block transcription [125]. Post-transcriptional 
function of the GR also has been shown to reduce mRNA levels by reducing mRNA stability 
of IL-4 and TNF-α [126, 127]. 
However, other studies have reported the contrary. Ramirez et. al. showed that pre-treatment 
with GCs enhanced type 2 cytokine expression following T cell activation [128], while 
another study showed a positive regulation of cytokines IL-4 and IL-10 when TEM cells were 
treated with GC in combination with CD3 stimulation [120]. Therefore, the effect of GC on 
cytokines appears to be more complex than simple suppression. 
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1.5.2 Glucocorticosteroid Receptor Regulated Protein-Protein Interactions 
The anti-inflammatory action also occurs through protein-protein interactions by binding AP-
1 and NFκB. These transcription factors are up-regulated during T cell activation to promote 
inflammatory function of lymphocytes [129]. NFκB is a pro-inflammatory transcription 
factor that regulates transcription of pro-inflammatory genes such as cyclooxygenase-2 
(COX-2) and TNF-α [130, 131]. NFκB also up-regulates expression of cell adhesion 
molecules on lymphocytes to allow lymphocytes into and through the tissues [132]. The GR 
can inhibit inflammation by binding directly to NFκB [133]. Even with the GR protein 
binding domain mutated, NF-kB was still inhibited by GR activation most likely through 
transcriptional regulation of IkB proteins [134]. AP-1 interacts with NFAT to regulate 
transcription of cytokines IL-5 and IL-13, while AP-1 can regulate transcription of IL-13 
independent of NFAT [135]. AP-1 and GR can mutually inhibit each other, as demonstrated 
by studies overexpressing AP-1 and GR.  
1.5.3 Glucocorticosteroid Mediated Apoptosis 
Apoptosis is dependent on the regulation of BCL family proteins and caspases to induce 
death [136]. Caspases- 2,3,6,7,8,9 and 10 all have the potential to be active during apoptosis 
depending on whether mode of cell death is triggered intrinsically or extrinsically [137]. For 
example, caspase-8 is activated during Fas mediated apoptosis and caspase-9 is activated 
during GC-induced apoptosis [138, 139]. Both caspase-8 and caspase-9 cleave procaspase-3, 
activating caspase-3 and leading to apoptosis [140]. 
GC-induced apoptosis is regulated by BCL-2 and BCL-xL expression in cells [141, 142]. 
Studies show that their reduction leads to apoptosis and BCL-2 and BCL-xL overexpression 
has been shown to produce GC resistant T cells [141, 142]. Overexpression of GILZ, a GC 
inducible gene, has been shown to be correlated with downregulation of BCL-xL mRNA and 
protein [141]. The ability of GCs to induce apoptosis is dependent on transcriptional 
upregulation of genes that inhibit anti-apoptotic proteins and downregulation of homeostatic 
proteins [141, 143]. Eosinophils showed dose and potency dependent apoptosis in response 
to GC treatment [144]. GCs such as hydrocortisone that have lower affinity for the GR were 
not able to induce apoptosis [144]. Interestingly, GCs inhibit apoptosis in neutrophils, with 
more potent GCs having a greater inhibitory effect [145]. Thus, the ability of GCs to regulate 
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apoptosis is dependent on GC potency and dose. GCs have also been shown to inhibit  T cell 
activation induced apoptosis through up-regulation of MKP-1 and GILZ [146]. T cell 
activation induces both AP-1 and NFκB to increase FAS-ligand expression leading to Fas-
mediated apoptosis [147]. Whether GCs induce or inhibit apoptosis is dependent on the 
specific pathways activated, which may explain the ability of GCs to induce apoptosis in 
eosinophils and inhibit apoptosis in neutrophils.  
 
 
 
 
 
 
 
 
Figure 2: Glucocorticosteroid mechanisms of action 
GCs binding to the GR leads to the nuclear translocation of the receptor by FKBP4. Once the 
receptor is in the nucleus it can homodimerize and bind to DNA to regulate transcription (1), 
bind transcription factors to inhibit transcription (2) or reduce mRNA stability (3). GR can 
also up-regulate transcription of genes that lead to apoptosis (4).   
1.5.4 Glucocorticosteroid Resistance in Asthma  
Severe asthmatics are deemed GC resistant because despite taking the highest recommended 
dose of GCs these patients show little to no control over their symptoms [2]. One of the 
difficulties of identifying mechanisms of GC resistance is the complexity GC- GR signaling 
in the various inflammatory cells. 
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Previous studies have reported that asthmatic patients have an elevated level of the dominant 
negative isoform of the GR beta (GRβ) in peripheral blood mononuclear cells (PBMCs) and 
T cells [148, 149]. GRβ binds to GREs and prevents GRα (commonly referred to as GR) 
from binding GREs, therefore inhibiting GC-mediated transcription [150]. Work completed 
in our laboratory showed that the levels of GRβ in CCRF-CEM cells are very low, ~10,000 
times less than GRα, and therefore unlikely to play a major role in T cells. This is a limitation 
of the previous studies identifying elevated GRβ in asthmatic patients, as they did not look at 
total GR levels [148, 149].  
In terms of T cells, GCs have been shown to induce apoptosis in resting T cells, but T cell 
activation inhibits GC induced apoptosis through NFAT and AP-1 up-regulation [129, 151]. 
IL-2, a T cell survival factor has also been shown to inhibit GC-induced apoptosis in T cells 
[152, 153]. IL-2 activates the AKT pathway similar to CRTh2 to inhibit GC-induced 
apoptosis [154]. IL-2 can also activate STAT5 which can bind and inhibit the GR [155]. TEM 
cells unable to produce IL-2 were shown to be more sensitive to GC-induced cell death 
[156]. Interestingly, severe asthmatics have also been shown to have higher levels of IL-2 
relative to mild/moderate asthmatics [157] and the type 2 cytokine IL-4 was shown to render 
Th2 cells GC resistant [74].  
1.6 Rationale   
Asthma is a disease characterized by chronic inflammation and is mostly controlled by GC 
treatment. Allergic asthma, the most common type of asthma is dominated by Th2 cell 
inflammation and Th2 dominant phenotypes are associated with the most severe form of 
asthma [26]. Severe asthmatic patients despite being prescribed the highest recommended 
dose of inhaled GCs and oral GCs show reduced lung function and lack of disease control. 
The anti-inflammatory function of GCs is mediated by transcriptional regulation, protein 
binding and apoptosis [14].  
To better understand why severe asthmatics are GC resistant, research has focused on 
identifying unique features of this asthma phenotype. Severe asthmatics have been shown to 
have higher abundance of CRTh2 mRNA and higher percentage of CRTh2+ cells in BAL 
relative to mild/moderate asthmatics [4]. The percentage of Th2 cells in the circulation was 
also higher in severe asthmatics relative to mild/moderate asthmatics [3]. While the 
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prevailing thought for GC mechanism of action in asthma is that they reduce Th2 cytokine 
production, our laboratory has observed a positive correlation between   the percentage of 
Th2 cells in the blood of asthmatic patients and the total daily dose of inhaled GCs [3, 121, 
123]. Collectively, these studies suggest there may be a link between the level of Th2 cells 
present in the lungs/circulation of asthmatic patients and their response to GC treatment. GCs 
could potentially promote Th2 cell phenotype similar to GC promotion of Tregs, or promote 
survival similar to the phenomenon seen with neutrophils [119, 145]. Understanding the 
function of GCs in Th2 cells can provide insight into the method of GC action and potentially 
GC resistance.   
1.7 Hypothesis & Objectives  
1.7.1 Hypothesis 
GC function in Th2 cells is dose dependent and varies based on state of T cell activation.  
1.7.2 Objectives 
Objective 1: To investigate dose dependent effects of GC on pro-inflammatory gene 
expression 
Daily dose of GCs showed a positive correlation with the percentage of Th2 cells in the 
blood of asthmatic patients [3]. Regulation of CRTh2 expression is an important determinant 
of Th2 cell function [96]. GCs primarily downregulate transcription of pro-inflammatory 
genes, but some studies have indicated otherwise [113, 119]. Understanding how GCs 
regulate CRTh2 and IL-13 expression can provide insight into how GCs reduce inflammation 
and/or how Th2 cells exhibit GC resistance.  
Hypothesis: Low dose GCs regulate CRTh2 and IL-13 expression.  
 
Objective 2: To determine if CRTh2 activation inhibits GC-mediated apoptosis 
GCs induce apoptosis in T cells through caspase-3 activation, the same pathway inhibited by 
CRTh2 activation [98, 142]. PGD2 and Th2 cells have been shown to be correlated with 
asthma severity, indicating that severe asthmatics have the highest level of PGD2 and Th2 
cells [3]. If PGD2 can inhibit GC-induced apoptosis this may be a way that Th2 cells become 
GC resistant and results in Th2 cells being sustained in vivo.   
Hypothesis: High dose GCs induce apoptosis that is regulated by PGD2.  
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Objective 3: To assess how T cell activation influences GR-mediated gene regulation 
T cell activation via dendritic cells is a major step in the development of chronic 
inflammation in allergic asthma [44]. Interestingly, pathways activated by CD3/CD28 
activation are in direct competition with pathways activated by GCs [129, 158]. GCs have 
been shown to downregulate secretion of type 2 cytokines by activated T cells [120]. T cell 
activation on the other hand has been shown to inhibit GC mediated transcription, but it is 
unclear if this also affects genes involved in GR signaling [159]. This can provide further 
clarification on the role T cell activation plays in GC resistance.   
Hypothesis: T cell activation regulates GR signaling genes.  
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Chapter 2  
2 Materials and Methods  
2.1 Cell Culture  
2.1.1 CCRF-CEM cells  
An immortalized leukemia CD4+ T cell line CCRF-CEM cells (CCL- 119) was purchased 
from American Type Culture Collection (VA, USA). These cells were seeded every 2 days at 
0.2x106cells/mL in RPMI 1640 media (Sigma Aldrich, ON, Canada) supplemented with 10% 
Fetal Bovine Serum (FBS) (Hyclone Scientific, ON, Canada) and 0.5% Penicillin, 
Streptomycin and glutamine (Gibco, ON, Canada).  
2.1.2 In Vitro Differentiated Primary Human Th2 cells 
For this thesis, experiments were performed on previously frozen in vitro differentiated Th2 
cells. Blood was obtained from healthy donors and PBMCs were isolated using Ficoll 
histopaque Plus (GE Healthcare, Sweden).  CD4+ cells were isolated by negative selection 
with a CD4+ cell Isolation Kit II (Miltenyi Biotech, CA, USA). CD4+ T cells were then 
differentiated first through activation for 3 days on plate bound anti-CD3 (clone UCHT1, 
1μg/mL) and anti-CD28 (clone 37407, 1μg/mL) in the presence of recombinant human 
5ng/mL rhIL-2 (R&D Systems, MN, USA), 10-20ng/mL rhIL-4 (R&D Systems, MN, USA), 
blocking antibody for IFNγ (polyclonal, 1µg/mL) and IL-12 (Clone C8.6, 1µg/mL).  After 
activation, cells were proliferated with cytokines (IL-2 and IL-4) and blocking antibodies 
(IFNγ and IL-12) for 4 days. Following the 7 days of differentiation, a CRTh2+ selection kit 
(Milteny Biotech, CA, USA) was used to enrich CRTh2+ cells using CRTH2-PE conjugated 
antibody (Miltenyi Biotech, CA, USA). CRTh2+ cells were sorted using a positive selection 
kit (CRTh2+ cell selection kit, Miltenyi Biotech, CA, USA) to obtain a purity of 98%. In 
vitro differentiated primary Th2 cells were cultured at 2x106 cells/mL in X-Vivo 15 media 
(Lonza, MD, USA) supplemented with 10% Fetal Bovine Serum (Wisent, QC, Canada), 
0.5% Penicillin, Streptomycin and glutamine (Gibco, ON, Canada) and 5ng/mL of IL-2 (MN, 
USA) with cells cycled on plate bound 1μg/mL of αCD3/αCD28 for 3 days or just 5ng/mL 
IL-2 for 4 days.   
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2.2 Experimental Set-up  
2.2.1 Resting Cell Experiments  
Experiments were set-up at 0.2x106cells/mL for CCRF-CEM cells and 1.3x106cells/mL with 
0-5ng/mL of IL-2 for in vitro differentiated Th2 cells. Cells were treated with 0.01μM-1μM 
dexamethasone (Sigma Aldrich, ON, Canada), 13, 14-dihydro-15-keto Prostaglandin D2 
(DK-PGD2) (Caymen Chemicals, MI, USA) and 0.01μM-1 μM of GC antagonist RU486 
(Sigma Aldrich, ON, Canada). Cells were harvested by washing with phosphate buffered 
saline (PBS) for RNA isolation or PBS flow cytometry activated cell sorting (FACS) (0.5% 
bovine serum albumin, 0.1% sodium azide, 3% FBS) for flow cytometry.  
2.2.2 Activated Cell Experiments 
Experiments were set-up at 0.2x106cells/mL during peak growth phase, day after cells were 
seeded. Cells were treated with 0.01μM-1μM dexamethasone (Sigma Aldrich, ON, Canada), 
20ng/mL of phorbol 12-myristate 130 acetate (PMA) (Sigma Aldrich, ON, Canada), and 
1μM ionomycin (Sigma Aldrich, ON, Canada). Cells were harvested by washing with 
Phosphate Buffered Saline (PBS) before pelleting cells for RNA isolation.  
2.3 Gene Expression  
2.3.1 Quantitative Real Time PCR (qRT-PCR) 
Taqman quantitative real-time polymerase chain reaction (qRT-PCR) was used to determine 
relative gene expression using complementary DNA (cDNA). This method uses a fluorescent 
reporter dye (5’) and a quencher (3’) attached to the reporter probe. As the Taq Polymerase 
elongates the template strand it cleaves the reporter from the probe, once separated from the 
quencher the probe fluoresces. This florescence is measured and reflects the mRNA 
abundance amplified at the end of the assay which is represented by cycle threshold (ct).  
To quantify mRNA levels, mRNA was extracted using RNeasy mini plus extraction kit 
(Qiagen, ON, Canada). RNA concentrations and quality were assessed using a nano-drop 
(Thermo Scientific). RNA samples with a 260/280 and 260/230 ratio greater than 1.8 were 
used for complimentary DNA (cDNA) synthesis. cDNA was synthesized using 400ng of 
mRNA template, iScript reverse transcriptase (BioRad, CA, USA), and RNAse/DNAse free 
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water (Lonza, MD, USA). cDNA synthesis was generated by priming for 5 min (25◦C), 
reverse transcription 30 minutes (42◦C) followed by RT inactivation 5 minutes (85◦C). 
Resulting cDNA was stored short term at 4◦C and long-term in -20◦C prior to qRT-PCR. 
Taqman gene expression assays (Life Technologies, CA, USA) for GAPDH 
(Hs02786624_g1), CRTh2 (Hs00173717_m1), IL-13 (Hs00174379_m1), FKBP5 
(Hs01561006_m1) and GR (Hs00353740_m1) were used. qRT-PCR reactions contained 2μL 
of cDNA, 10μL of Taqman Mastermix (Applied Biosystems, CA, USA) and 7μL of 
RNase/DNase free water. Amplification was performed with the full reaction on a CFX 96: 
UNG Activation 2 minutes (50◦C), polymerase activation 20 seconds (95◦C), denature within 
3 seconds, anneal/extend 30 seconds (60◦C) (for 40 cycles). Data was analyzed using cycle 
threshold (Ct) relative to housekeeping gene GAPDH. Fold increase relative to control 
condition was assessed for experimental treatments using 2-∆∆Ct.  
2.4 Fluorescent Staining  
2.4.1 Surface Expression 
Flow cytometry uses laser technology to assess physical and chemical properties of single 
cells suspended in fluid. Fluorescent labelled antibodies are used to identify specific protein 
or chemical markers. The fluorochromes are excited by lasers of specific wavelength and the 
light emitted is then detected and assessed. Presence and intensity of light emission is used to 
determine existence and relative abundance of a protein or chemical marker.   
Surface expression of CRTh2 was assessed using flow cytometry. Cells (0.5x106cells) were 
washed (PBS FACS) at 900rpm. Cells were pelleted and re-suspended (PBS FACS) at 
5x106cells/ml. Cells were blocked for 45 minutes (room temperature) with 3mg/mL of Rat 
IgG (Cederlane ON, Canada). Blocking was followed by cell staining with 75ng/mL of 
CRTh2 Alexa647 antibody (BM16-rat IgG2a, Cederlane ON, Canada) or 75ng/mL of isotype 
rat IgG2a Alexa647(Cederlane ON, Canada) for 30 minutes on ice. Cells were then washed 
with 1mL of PBS FACS for 5 minutes at 900rpm and then re-suspended in 200uL of PBS 
FACS and fixed with 200uL of 4% paraformaldehyde (final 2%). Data were presented as % 
parent and mean fold intensity (MFI). MFI was calculated controlling for isotype (MFI= 
[Mean Intensity Antibody – Mean intensity Isotype]/ Mean intensity Isotype). 
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2.4.2 Apoptosis 
Experiments assessing apoptosis were set-up the day cells were re-seeded. Cells were treated 
with 0.1µM-1µM dexamethasone treatment in the presence or absence of antagonist RU486 
for 24 or 48 hours. Experiments testing PGD2 were pre-treated with DK-PGD2 30 minutes 
prior to dexamethasone treatment.  
Caspase 3/7(Cederlane ON, Canada) assay uses a fluorescently tagged peptide which enters 
the cell and is cleaved by active caspase 3/7. The fluorescent dye is cleaved from the peptide 
and can bind directly to DNA to emit fluorescence. The Sytox assay (Cederlane ON, Canada) 
is a dye that can bind directly to DNA under conditions of cell death when cellular and 
nuclear membrane integrity is compromised.  
Cells (1mL) were collected and placed into 1.5mL Eppendorf tubes. 2 drops of caspase 3/7 
and 1μL of Sytox was added to cells and mixed by inversion. Stains were incubated for 40 
minutes (room temperature). Data were presented as percentage of cells positive for each 
fluorescent stain.  
Apoptosis and cell death following experimental treatments was assessed using Annexin V 
and 7AAD, respectively. Cells were collected (0.5x106cells) and washed with PBS FACS at 
900rpm for 10 minutes. Cells were re-suspended in 100μL of Annexin V binding buffer 
(10mM Hepes, 140mM NaOH, 2.5mM CaCl2) at 5x106cells/mL. Double stain of 1μL of 
Annexin V and 10μL of 7AAD was added to each condition. Cells were incubated for 15 
minutes (room temperature). After incubation cells were diluted with 400μL of Annexin V 
binding buffer. Data were presented as percentage of positive cells of parent population. 
2.5 Statistical Analysis 
All data were represented as mean + standard error. Unpaired and paired t tests or one-way 
Anova were used to identify significance between conditions. Tukey’s Honest Significant 
Difference (HSD) test was used to identify significant differences between conditions. P 
values lower than 0.05 were considered significant differences.  
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Chapter 3  
3 Results 
Allergic asthma is mostly dominated by Th2 cell mediated inflammation [26]. GCs are the 
most common treatment for allergic asthma but the regulation of Th2 cells by GCs has not 
been well characterized. In this study, we examined the effect of GCs on Th2 cells with a T 
cell line (CCRF-CEM) that models a Th2 gene expression profile and validated these 
findings with an in vitro differentiated primary Th2 cell line. Two major functions of the GR 
are regulating mRNA transcripts either through transcription or stability and inducing 
apoptosis [14]. The GR can regulate transcription of genes by binding positive GREs or 
negative GREs to increase or decrease transcription, respectively [113]. GR mediated 
apoptosis is initiated by activation of the caspase-3 enzyme [160]. Interestingly, CRTh2 
activation by PGD2 has been shown to inhibit caspase-3 dependent apoptosis in response to 
IL-2 starvation [98]. This indicates that GR mediated apoptosis may be inhibited in Th2 
cells by CRTh2 activation. To have a complete understanding of the regulation of Th2 cells 
by GCs, we must determine GC regulation of mRNA in Th2 cells activated via CD3/CD28. 
T cell activation has been shown to inhibit both GR mediated transcription and apoptosis 
through the up-regulation of AP-1 and NFκB [133, 134, 161]. GR self-regulation through 
transcription of FKBP5 and GR is essential to sustaining GR function, whether this is 
affected by T cell activation is unclear [115, 162]. The study aims to understand the 
regulation of Th2 cells by GCs to enhance our knowledge of how GCs affect Th2 dominant 
inflammation in the airways.  
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3.1 CCRF-CEM Cells – A Th2-like cell line 
We chose to initiate our study of GC using a cell line because of the relative ease of cell 
culture and their accelerated growth (typically doubling daily). To choose a T cell line we 
reviewed T cells commonly used in the literature. The CCRF-CEM cell line was chosen 
based on its CRTh2 expression relative to other CD4+ T cells (Figure 3). CCRF-CEM cells 
are an acute lymphoblastic leukemia CD4+ T cell line derived from a 4-year-old female 
patient.  Expression of CRTh2 was confirmed and other important Th2 genes (GATA3 and 
IL-13) were assessed relative to Jurkat T cells, another cell line commonly used to study T 
cell function [163]. We found that CCRF-CEM cells had higher mRNA transcript levels of 
CRTh2 and GATA3 compared to Jurkat cells (Figure 3A). Activation using PMA and 
ionomycin of CCRF-CEM cells demonstrated higher IL-13 mRNA levels relative to Jurkat 
cells (Figure 3B). These results identified that CCRF-CEM cells are a better model to study 
Th2 cell regulation by GCs compared to the Jurkat T cell line.  
A B  
 
 
 
 
 
 
Figure 3: Th2 gene expression of Th cell lines 
Expression of Th2 genes in CCRF-CEM and Jurkat T cells were assessed using qRT-PCR. 
The basal expression of CRTh2 and GATA3 (A) and expression of IL-13 in response to T 
cell activation (B) was determined. Transcript levels are presented as 2-∆∆Ct  and normalized 
to housekeeping gene GAPDH and represent as mean fold difference + standard error (SE). 
Statistical difference (p<0.05) detected by Student’s t-test. n=5.  
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3.2 GC Regulation of CRTh2 Expression 
CRTh2 is a marker of Th2 cells and its expression exemplifies a fully differentiated helper T 
cell subset [86, 164]. CRTh2 expression by Th2 cells is important because CRTh2 mediates 
chemotaxis, cytokine production and cell survival [95, 98, 99]. So far, GATA3 has been the 
sole transcription factor shown to regulate CRTh2 transcription [165]. Sequence variants of 
CRTh2 transcripts in the African American population have been associated with increased 
stability and greater risk of asthma development [91]. These findings build on the data 
identifying higher CRTh2 mRNA and CRTh2+ cells in the lungs of severe asthmatics that 
take the highest dose of GCs [3, 4]. A positive correlation was also seen between the daily 
dose of GCs and percentage of Th2 cells in circulation [3]. One of the main functions of the 
GR is regulation of transcription by binding GREs [113]. Interestingly, preliminary data in 
our lab generated using the Encyclopedia of DNA Elements (ENCODE) show that DNASE 1 
hypersensitive sites on the CRTh2 promotor contain putative GRE (Naghdi, unpublished). 
This provided further incentive to determine whether GCs regulate transcription of CRTh2.     
3.2.1 Dexamethasone Regulates CRTh2 mRNA in CCRF-CEM cells 
Dexamethasone is among the most potent oral GCs available clinically and has a half-life of 
36-54 hours [166, 167]. Compared to prednisone which is a common oral GC prescribed for 
asthma treatment, dexamethasone is 5 times more potent and has double the half-life [167]. 
Thus, we thought dexamethasone would be the best GC to use to help us understand the 
potential of the GR signaling pathway to regulate transcription.  The CRTh2 locus has been 
shown to contain putative GR binding sites.  Determining whether the GR regulates CRTh2 
transcription will help us to understand how GCs regulate Th2 cell function. The level of 
CRTh2 mRNA transcripts in response to kinetic and titration experiments of dexamethasone 
were performed using CCRF-CEM cells (Figure 4). No changes in CRTh2 mRNA transcript 
levels were seen at 2 hours (Figure 4A), there were reduced levels at 6h (Figure 4B) and no 
change at 12 hours (4C) of dexamethasone treatment. CRTh2 mRNA levels were higher in 
response to GC treatment of 0.01μM-1μM after 24 hours (Figure 4D). Interestingly the 
increase in CRTh2 transcript levels plateaued at 0.01μM dexamethasone. This increase in 
CRTh2 mRNA transcripts was inhibited by RU486 (Figure 4E), an antagonist that blocks 
GRE binding, indicating that the GR directly regulates transcription of CRTh2.  
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Figure 4: CRTh2 mRNA transcript levels in response to dexamethasone treatment 
CRTh2 mRNA transcript levels were assessed by qRT-PCR after 2 hours (A), 6 hours(B), 12 
hours (C), and 24 hours (D) of dexamethasone treatment in CCRF-CEM cells. The antagonist 
RU486 was added with dexamethasone to inhibit GR activity (E). Transcript levels are 
presented as 2-∆∆Ct  and normalized to housekeeping gene GAPDH and represent mean fold 
difference relative to vehicle + SE. Statistical difference (p<0.05) detected by one way 
ANOVA. V=vehicle (ETOH 0.004%); n =3-19.  
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3.2.2 Hydrocortisone Regulation of CRTh2 mRNA in CCRF-CEM cells 
Hydrocortisone is found naturally in the body and is produced in response to stress. 
Compared to dexamethasone, hydrocortisone is a weaker GR agonist [166]. We wanted to 
determine whether GR regulation of CRTh2 mRNA was dependent on GC potency. The 
level of CRTh2 mRNA transcripts appeared to increase, though this change was not 
statistically significant, due to the lack of statistical power.  
 
 
 
 
Figure 5: CRTh2 mRNA transcript levels in response to hydrocortisone treatment 
CRTh2 mRNA transcript levels were assessed by qRT-PCR after 24 hours of hydrocortisone 
treatment in CCRF-CEM cells. Transcript levels are presented as 2-∆∆CT, normalized to 
housekeeping gene GAPDH and represented as mean fold difference relative to vehicle + SE. 
HC= hydrocortisone; V=vehicle (ETOH 0.004%); n =3.  
3.2.3 Dexamethasone Regulates FKBP5 mRNA levels 
FKBP5 which is a chaperone protein that keeps the GR in the cytoplasm and in an active 
state within the GR heterocomplex [110]. To sustain GR function, there is feed-forward 
regulation by the GR that increases FKBP5 transcription [115]. FKBP5 was used as a 
positive control for GR-induced effect on transcripts to assess the level of GR function at 
different concentrations. We assessed FKBP5 mRNA transcript levels to determine GC 
regulation in CCRF-CEM cells (Figure 6). A dose dependent increase in FKBP5 mRNA 
transcript levels was seen, with the first increase at 6 hours (Figure 6A) and continual 
increase after 24 hours (Figure 6B). Incorporation of RU486 with dexamethasone for 24 
hours inhibited the increase in FKBP5 mRNA transcript levels (Figure 6C). FKBP5 mRNA 
transcript levels showed a dose dependent induction in response to dexamethasone treatment 
in CCRF-CEM cells.   
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Figure 6: FKBP5 mRNA transcript levels in response to dexamethasone treatment 
FKBP5 mRNA transcript levels were assessed over time with qRT-PCR after 6 hours (A) 
and 24 hours (B) of dexamethasone treatment in CCRF-CEM cells. The antagonist RU486 
was added with dexamethasone to inhibit GR activity (C). FKBP5 mRNA transcript levels 
were assessed using 2-∆∆Ct and normalized to housekeeping gene GAPDH. Data represented 
as mean fold difference relative to vehicle + SE. Statistical difference (p<0.05) detected by 
one-way ANOVA. V=vehicle (ETOH 0.004%); n =3-6.  
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3.2.4 Dexamethasone Regulation of CRTh2 Surface Expression in CCRF-
CEM cells  
CRTh2 is a seven-transmembrane spanning G-protein coupled receptor, thus its expression 
on the membrane requires the work of multiple folding and transport proteins [168]. Previous 
research using transfected T cells demonstrated that CRTh2 mRNA levels are reflected by 
total protein levels in the cell [80]. We treated CCRF-CEM cells with dexamethasone and 
assessed whether the change in CRTh2 mRNA levels we detected (Figure 4D) are reflected 
by the CRTh2 surface expression (Figure 7).  After 24 hours of dexamethasone treatment 
there were no significant changes in the percentage of cells positive for CRTh2 (Figure 7A) 
or the abundance of receptors per cell, represented by mean fold intensity (Figure 7B). These 
results indicate that the changes in CRTh2 mRNA did not translate to surface expression. 
 
A B 
   
 
 
 
Figure 7: CRTh2 surface expression in response to dexamethasone treatment 
Expression of CRTh2 on the cell surface was assessed using flow cytometry. CRTh2 levels 
were determined in response to dexamethasone treatment in CCRF-CEM cells for 24 hours. 
The data were represented as percentage of cells expressing CRTh2 (A) and mean fold 
intensity representing the abundance of CRTh2 receptors per cell (B). Data represented as 
means + SE. V=vehicle (ETOH 0.004%); n = 7.  
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3.2.5 Dexamethasone Regulates CRTh2 mRNA in Primary Th2 cells 
Due to the lack of agreement between CRTh2 mRNA and protein in CCRF-CEM cells, we 
next turned to in vitro differentiated Th2 cells as a more physiologically relevant cell type to 
assess the GC effect on CRTh2 expression. Transcript levels of CRTh2 and FKBP5 in 
response to dexamethasone treatment for 24 hours were assessed (Figure 8). CRTh2 mRNA 
levels (Figure 8A) were higher in response to dexamethasone treatment at concentrations of 
0.01μM and above but did not differ between doses. The fold induction in primary Th2 cells 
was higher (~4 fold) then what was previously seen with dexamethasone treatment of CCRF-
CEM cells (~2 fold; Figure 4D). FKBP5 mRNA transcript levels also increased in response 
to dexamethasone in a dose dependent manner. The results replicate the mRNA changes seen 
in CCRF-CEM cells, but show that in primary Th2 cells GC upregulates CRTh2 mRNA to an 
even greater extent.  
A B 
 
 
 
 
 
Figure 8: mRNA transcript levels in primary Th2 cells  
CRTh2 (A; n=5) and FKBP5 (B; n=3) mRNA transcript levels were assessed using qRT-
PCR in response to dexamethasone. Transcript levels are presented as 2-∆∆Ct and normalized 
to housekeeping gene GAPDH and represent mean fold difference relative to vehicle + SE. 
Statistical difference (p<0.05) detected by one-way ANOVA. V=vehicle (ETOH 0.004%).  
 
30 
 
 
3.2.6 Dexamethasone Regulates CRTh2 Surface Expression in Primary Th2 
cells 
CRTh2 mRNA transcripts were increased in both CCRF-CEM and primary Th2 cells in 
response to 24 hours of dexamethasone treatment. Although previous studies have indicated 
that CRTh2 mRNA changes are reflected at the protein level, this was not seen with CRTh2 
surface expression in CCRF-CEM cells (Figure 7) [80]. To determine whether changes in 
CRTh2 mRNA transcript levels are reflected with CRTh2 surface expression we treated 
primary Th2 cells with dexamethasone (Figure 9). When assessing all doses of 
dexamethasone together we saw that with a one-way ANOVA there were no significant 
changes in percentage of cells positive for CRTh2 (Figure 9A) or the abundance of receptors 
per cell, represented by mean fold intensity (Figure 9C). On the other hand, when we looked 
at the vehicle in comparison to the lowest concentration of dexamethasone needed to see 
mRNA changes (Figure 8A) we saw a significant difference using a Paired t-test in both the 
percentage of cells positive for CRTh2 (Figure 9B) and abundance of CRTh2 receptors per 
cell (Figure 9D). This indicates that at low concentrations of dexamethasone CRTh2 surface 
expression is also increased.   
3.2.7 Dexamethasone Regulates IL-13 Expression in Primary Th2 cells 
The ability of GCs to regulate CRTh2 expression may help promote Th2 inflammation, 
which is contrary to previous in vivo studies showing that GCs reduce type 2 cytokines [127, 
169]. Even in the case of Th2 high asthma the reduction of IL-13 in response to GCs is an 
indicator of steroid sensitivity [26]. As such, we wanted to determine whether GCs reduce 
IL-13 mRNA levels despite increasing CRTh2 mRNA. To test whether GCs can reduce IL-
13 mRNA levels we treated primary Th2 cells with dexamethasone for 24 hours (Figure 10) 
and found that there was a dose dependent reduction in IL-13 mRNA levels at the lowest 
concentration of dexamethasone (0.01µM). These data show GCs can reduce IL-13 
expression but at the same time increase CRTh2 expression.  
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Figure 9: CRTh2 surface expression in response to dexamethasone treatment 
Expression of CRTh2 on the surface of the cell was assessed using flow cytometry. CRTh2 
levels were determined in response to dexamethasone treatment for 24 hours. The data were 
represented as percentage of cells expressing CRTh2 (A, C) and mean fold intensity 
representing the abundance of CRTh2 receptors per cell (B, D). Data represented as means + 
SE V=vehicle (ETOH 0.004%); Statistical difference (p<0.05) detected by using paired T-
test. n = 7.    
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Figure 10: IL-13 mRNA levels in primary Th2 cells in response to dexamethasone 
IL-13 mRNA levels were assessed using qRT-PCR in primary Th2 cells treated with 
dexamethasone for 24 hours. Transcript levels are presented as 2-∆∆CT, normalized to 
housekeeping gene GAPDH and represented as mean fold difference relative to vehicle + SE. 
V=vehicle (ETOH 0.004%); n =5.  
3.3  Glucocorticosteroid Induced Apoptosis in Th2 cells 
In addition to suppressing Th2 cytokines, another function of GCs is the ability to induce 
apoptosis in inflammatory cells in a dose and time dependent manner [144]. GC-induced 
apoptosis in naïve and memory T cells has been well documented but no studies have been 
completed specifically in Th2 cells [141-143]. PGD2 binding CRTh2 activates the PI3K 
pathway which has been shown to inhibit apoptosis induced by IL-2 starvation in Th2 cells 
by inhibiting BAD interference of anti-apoptotic BCL proteins [98]. Downregulation of BCL 
proteins induces GC-induced apoptosis, thus there is competition between pathways 
activated by GCs and PGD2 [98, 141, 151]. Severe asthmatics who take the highest dose of 
GCs have been shown to have a higher level of PGD2 relative to other asthmatics [4]. If 
PGD2 can inhibit GC-induced apoptosis, Th2 cells may be sustained in severe asthmatics 
even though they take high dose GCs. As such, we wanted to test whether CRTh2 signaling 
could inhibit GC-induced apoptosis and render Th2 cells GC resistant.  
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3.3.1 Dexamethasone Regulates Apoptosis in CCRF-CEM cells 
The effect of GCs is dependent on dose and exposure time and most importantly dependent 
on cell type as demonstrated by opposing apoptotic effects seen in eosinophils versus 
neutrophils [144, 145]. To determine whether PGD2 can inhibit GC-induced apoptosis it was 
important to first establish the dose and time of exposure needed to induce apoptosis. CCRF-
CEM cells were treated with dexamethasone for 24 and 48 hours to assess the ability of GCs 
to induce apoptosis. To test whether cells were undergoing apoptosis and cell death we used 
Caspase 3/7 and Sytox fluorescent stains, respectively. After 24 hours of exposure to various 
concentrations of dexamethasone treatment there were no changes in apoptosis (Figure 11A) 
or cell death (Figure 11B). After 48 hours of 1μM dexamethasone there was a significant 
increase in apoptosis (Figure 11C) and cell death (Figure 11D). Induction of apoptosis was 
related directly to the ability of GCs to influence transcription as the effect was inhibited by 
RU486.  
GC-induced apoptosis results from the release of cytochrome C and downstream activation 
of caspase-3 to induce cell death [170]. We wanted to use a more sensitive assay to ensure 
we did not miss any apoptotic effects after 24 hours of dexamethasone treatment. We used 
the stain Annexin V which binds phosphatidylserines to detect early apoptotic changes at the 
cell surface of viable cells [106]. To do this CCRF-CEM cells were treated with various 
concentrations of dexamethasone (24 and 48 hours) and stained for Annexin V and 7AAD 
(Figure 13). Similar to Figure 11 there was no significant apoptosis or cell death after 24 
hours of dexamethasone treatment (Figure 12A,12B), but again we see that after 48 hours of 
1µM dexamethasone treatment there is an increase in both apoptosis and cell death (Figure 
12C, D). Induction of apoptosis by GCs was inhibited by antagonist RU486.  
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Figure 11: Dexamethasone induced apoptosis in CCRF-CEM cells 
CCRF-CEM cells were treated with dexamethasone for 24 and 48 hours with and without 
antagonist RU486 to determine apoptosis and cell death using fluorescent stains. After 24 
hours the percentage of caspase 3/7 positive cells (A) and Sytox positive cells (B) indicated 
apoptosis and cell death, respectively. After 48 hours the percentage of caspase 3/7 positive 
cells (C) and Sytox positive cells (D) indicated apoptosis and cell death, respectively. Data 
represented as means + SE. Dex = dexamethasone; V=vehicle (ETOH 0.004%); Statistical 
difference (p<0.05) detected by using one way ANOVA. n = 4.    
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Figure 12: Dexamethasone induced apoptosis  
CCRF-CEM cells were treated with dexamethasone for 24 and 48 hours with and without 
antagonist RU486 to determine apoptosis and cell death using flow cytometry. Percentage of 
Annexin V positive cells identified dexamethasone induced apoptosis for 24 hours (A) and 
48 hours (C). Cell death was assessed by cells positive for 7AAD after 24 hours (B) and 48 
hours (D). Data represented as mean fold difference relative to vehicle + SD; dex = 
dexamethasone; V=vehicle (ETOH 0.004%); Statistical difference (p<0.05) detected by 
using one way ANOVA. n = 4. 
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3.3.2 PGD2 Does Not Regulate Dexamethasone Induced Apoptosis in 
CCRF-CEM cells 
GR induction of apoptosis and CRTh2 inhibition of apoptosis are both are regulated by 
similar pathways but in the opposite manner [98, 141]. PGD2 binding to CRTh2 activates 
AKT signaling which inhibits caspase-3 mediated apoptosis, while GCs induce caspase-3 
mediated apoptosis [98, 141]. CRTh2 has been shown to inhibit apoptosis but only in the 
context of IL-2 starvation [98]. To determine whether CRTh2 and GC activated pathways 
compete to maintain Th2 cell survival, we pre-treated CCRF-CEM cells with CRTh2 specific 
agonist, the PGD2 metabolite DK-PGD2 before treating with dexamethasone for 48 hours 
(Figure 13). DK-PGD2 did not reduce the percentage of Annexin V+ cells in response to GC 
treatment. These results may be due to a limitation of the CCRF-CEM cells ability to regulate 
CRTh2.  
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Figure 13: DK-PGD2 does not inhibit GC-induced apoptosis in CCRF-CEM cells 
CCRF-CEM cells were pre-treated with DK-PGD2 and then dexamethasone for 48 hours. 
Data represented as means + SE. Early apoptosis was determined by Annexin V positive 
cells. V=vehicle (ETOH 0.004%); Statistical difference (p<0.05) detected by using one-way 
ANOVA. n=5.  
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3.3.3 IL-2 Inhibits Glucocorticosteroid Induced Apoptosis in Primary Th2 
cells 
IL-2 is a survival factor that is required to maintain T cells in culture [154]. IL-2 signals 
through AKT to inhibit apoptosis induced by GCs [171]. We have determined that 1µM 
dexamethasone was required to induce apoptosis in CCRF-CEM cells, but these cells were 
not cultured with IL-2. We needed to determine the concentration of IL-2 needed to maintain 
Th2 cells but still leave them susceptible to apoptosis. We treated cells with decreasing 
concentrations of IL-2 with and without dexamethasone and assessed percentage of Annexin 
V+ cells (Figure 14). Cells treated with decreasing concentrations of IL-2 (5-0ng/mL) show a 
dose response to 1μM dexamethasone induced apoptosis. 0ng/mL of IL-2 had significant 
apoptosis in the absence of dexamethasone. Thus, these results indicate that 1.25ng/mL of 
IL-2 sustained Th2 cells while still permitting GC sensitivity.  
 
 
 
 
 
 
 
 
Figure 14: IL-2 inhibits dexamethasone induced apoptosis  
The ability of dexamethasone to induce apoptosis with varying amounts of IL-2 was 
identified by Annexin V positive cells using flow cytometry. Primary Th2 cells were treated 
with dexamethasone and decreasing amounts of IL-2 for 48 hours to assess cell apoptosis. 
Data represented as means + SE. V= vehicle (0.04% ETOH). Statistical difference (p<0.05) 
detected by using one way ANOVA and Tukey’s HSD test. n=3.  
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3.3.4 PGD2 Does Not Regulate Dexamethasone Induced Apoptosis in 
Primary Th2 cells  
CCRF-CEM cells that were pre-treated with DK-PGD2 did not show any changes in 
dexamethasone induced apoptosis. Primary Th2 cells were used to replicate the previous 
experiments assessing PGD2 inhibition of apoptosis. In these experiments, Th2 cells were 
cultured in 1.25ng/mL of IL-2 which we determined was sufficient to maintain Th2 cells and 
render cells susceptible to GCs (Figure 14). Primary Th2 cells were pre-treated with DK-
PGD2 followed by dexamethasone treatment and assessed for apoptosis using Annexin V 
staining. However, there were no differences in the percentage of Annexin V+ cells in 
response to dexamethasone treatment after DK-PGD2 pretreatment (Figure 15).  
 
 
 
 
 
 
 
Figure 15: DK-PGD2 does not inhibit dexamethasone induced apoptosis 
To assess the ability of CRTh2 signaling to inhibit apoptosis, primary Th2 cells cultured with 
1.25ng/mL of IL-2 were pre-treated with DK-PGD2 and then treated with dexamethasone. 
Early apoptosis was determined by Annexin V positive cells using flow cytometry. Data 
represented as means + SE; V=vehicle (ETOH 0.004%); n = 3. 
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3.4 Glucocorticosteroid Regulation of Transcription in Activated T 
cells 
A large component of chronic inflammation in asthma is the constant activation of Th2 cells 
via dendritic cells [44]. CD3 and CD28 co-stimulation of Th2 cells up-regulates transcription 
factors NFAT, AP-1 and NFκB to induce cytokine production and regulate inflammation [53, 
158, 172]. Production of type 2 cytokines can be inhibited by GCs as indicated in literature 
and demonstrated with our own work (Figure 10) [127].  Interestingly, AP-1 and NFκB have 
both been shown to inhibit GR induced transcription [134, 161]. The GR has also been 
shown to reciprocally inhibit AP-1 and NFκB, as GC treatment of T cells increased the 
threshold for T cell activation [173]. Thus, GR and the T cell activation pathways compete 
and interfere with each other. Severe asthmatics have the highest percentage of Th2 cells in 
circulation, thus if T cell activation inhibits GC regulation of Th2 cells, chronic exposure to 
allergens may render Th2 cells GC insensitive [3]. To fully understand how GCs regulate 
Th2 cells we wanted to look at GR function in the context of activated Th2 cells.  
3.4.1 Dexamethasone Regulates IL-13 mRNA in CCRF-CEM cells 
T cell activation induces expression of type 2 cytokines IL-4, IL-5, and IL-13 [55, 135]. 
Interestingly, activated T cells have been deemed GC resistant but cytokines can be inhibited 
by GCs [159, 174]. Our previous results indicated that GCs could reduce IL-13 mRNA levels 
in primary Th2 cells, even at low dose (0.01µM; Figure 11). If T cell activation inhibits GC 
function, then the extent of IL-13 regulation by GCs may be repressed. To determine whether 
GCs can inhibit cytokine expression with T cell activation, CCRF-CEM cells were activated 
with PMA and ionomycin (Figure 16). IL-13 mRNA transcript levels were reduced in 
response to dexamethasone treatment though the reduction was only about 30% compared to 
(80%) reduction seen in primary Th2 cells. These results suggest that the GR still retains its 
ability to inhibit IL-13 production after T cell activation.  
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Figure 16: Dexamethasone reduces IL-13 mRNA transcript levels in activated T cells 
The dexamethasone response of activated CCRF-CEM cells was assessed using qRT-PCR 
after 24 hours. IL-13 mRNA transcript levels were assessed using 2-∆∆Ct and normalized to 
housekeeping gene GAPDH. Data represented as mean fold difference relative to vehicle + 
SE. P= PMA; I= ionomycin; V=0.004% ETOH); Statistical difference (p<0.05) detected by 
using one-way ANOVA. n=5.   
3.4.2 T cell Activation Interferes with Dexamethasone Regulation of GR 
Signaling Genes in CCRF-CEM cells 
Upon GC binding, the GR increases transcription of FKBP5 and GR, to sustain GR function. 
Although T cell activation has been shown to inhibit GR mediated transcription, it has not 
been shown whether there is a similar effect on the feed forward loop of GCs increasing 
expression of genes within its own signaling pathway. To test this CCRF-CEM cells were 
activated with PMA and ionomycin to mimic CD3 and CD28 mediated T cell activation and 
with or without dexamethasone. The level of FKBP5 and GR mRNA transcripts in response 
to dexamethasone treatment in resting and activated cells was assessed (Figure 17). As 
expected both FKBP5 and GR mRNA transcript levels were increased in response to 
dexamethasone treatment. But, with the addition of PMA and ionomycin the dexamethasone 
effect on the level of FKBP5 and GR mRNA transcripts were reduced. This builds on 
previous studies, as these data demonstrate that activation of T cells reduces GR mRNA 
transcripts and thereby GR activity, to render Th2 cells less sensitive to GCs.  
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Figure 17: Dexamethasone regulation is inhibited by T cell activation 
The dexamethasone response in activated CCRF-CEM cells was assessed using qRT-PCR 
after 24 hours. FKBP5 (A) and GR (B) mRNA transcript levels were assessed using 2-∆∆Ct 
and normalized to housekeeping gene GAPDH. Data represented as mean fold difference 
relative to vehicle + SE. V= 0.004% ETOH; P= PMA; I = Ionomycin; Statistical difference 
(p<0.05) detected by using one way ANOVA. n=5.  
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3.4.3 Dexamethasone Does Not Regulate CRTh2 Expression in Activated T 
cells 
One of the novel findings of this study was the identification that GCs regulate CRTh2 
mRNA levels (Figure 4). This GC regulation of CRTh2 may have vast implications in 
relevance to Th2 cell function [95, 98, 99]. Interestingly, CRTh2 expression has been shown 
to be downregulated by T cell activation [80]. We have seen that T cell activation reduces 
GR activity as demonstrated by lower levels of FKBP5 and GR mRNA transcripts (Figure 
18). Despite reduced GR signaling genes these conditions did not completely inhibit the 
ability of GCs to reduce IL-13 mRNA levels (Figure 16). To determine whether GCs could 
increase CRTh2 expression in the presence of T cell activation we treated CCRF-CEM cells 
with dexamethasone and PMA and Ionomycin (Figure 18). As previously shown, CRTh2 
mRNA levels were increased with dexamethasone treatment but with the addition of PMA 
and ionomycin there was significant drop that was reversed by dexamethasone.   
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Figure 18: Dexamethasone induction of CRTh2 is inhibited by T cell activation 
The dexamethasone response in activated CCRF-CEM cells was assessed using qRT-PCR 
after 24 hours. CRTh2 mRNA transcript levels were assessed using 2-∆∆Ct and normalized to 
housekeeping gene GAPDH. Data represented as mean fold difference relative to vehicle + 
SE. V= 0.004% ETOH; P= PMA; I = Ionomycin; Statistical difference (p<0.05) detected by 
using one way ANOVA. n=5.  
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Chapter 4 : Discussion 
4 Summary 
Severe asthmatic patients have a higher percentage of CRTh2+ cells in the airways and Th2 
cells in circulation, relative to mild/moderate asthmatics [3, 4]. Interestingly, Palikhe et al 
identified a positive correlation between the percentage of Th2 cells in the blood of 
asthmatics and the daily dose of inhaled GCs taken [3]. Naturally, this finding provided 
incentive to study the effects of GC on Th2 cells.  
An immortalized CD4+ T cell line (CCRF-CEM) and in vitro differentiated primary Th2 cells 
were examined with varying concentrations and times of exposure to dexamethasone and its 
antagonist RU486. We found that the dexamethasone effect on gene expression and 
apoptosis was concentration dependent. Low concentration of GCs (0.01µM) increased the 
level of CRTh2 mRNA and surface expression after 24 hours, while reducing the expression 
of the type 2 cytokine IL-13. Th2 cells exposed to high concentration GC (1µM) for 48 hours 
triggered apoptosis, but this was not inhibited by PGD2. We also examined GC regulation of 
mRNA transcripts in response to T cell activation, which has been shown to reduce GC 
mediated transcription and apoptosis [134, 159]. We found that IL-13 expression was 
reduced (30%) with dexamethasone in activated CCRF-CEM cells and to a greater extent in 
primary cells (80%). These data suggest that activation may dampen Th2 cell response to 
GCs. Overall the effect of GCs on Th2 cells proves to be complex and to depend on dose, 
time of exposure and state of activation. This study provides further insight into the potential 
mechanisms of GC regulation of Th2 cells. Insufficient dose of inhaled GC in vivo may result 
in higher expression of CRTh2, leading not only to ineffective anti-inflammatory action but 
enhancing the pro-inflammatory potential of Th2 cells.  
4.1 Glucocorticosteroids Regulate Th2 cell expression of CRTh2 
GCs regulate transcription by binding GREs [150]. Whether GCs mediate up-regulation or 
down-regulation of gene transcription is dependent on dose, time of exposure and cell type 
[113, 166]. Despite its use as an anti-inflammatory drug GCs have been shown to increase 
transcription of pro-inflammatory genes [119, 175].  
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We examined the effect of the GC dexamethasone on CCRF-CEM cells at various time 
points (24-48 hours) and concentration (0.01-1μM). We found that a concentration of 
dexamethasone of 0.01μM and higher was associated with more CRTh2 mRNA transcripts 
after 24 hours (2-fold). This upregulation of CRTh2 transcripts was not observed with 
hydrocortisone, which is a less potent GR agonist then dexamethasone [166]. Further 
replicates and/or higher concentrations of hydrocortisone may have been necessary to see 
significant changes in CRTh2 mRNA. The level of CRTh2 mRNA transcript plateaued with 
the lowest dose of dexamethasone (0.01µM), which was the minimum concentration needed 
to induce FKBP5, a gene known to be regulated at the transcriptional level by GCs [114]. 
Interestingly, after 24 hours FKBP5 showed a dose response with a maximum increase (8-
fold). This suggests that the GR regulation of CRTh2 and FKBP5 differ. The plateau of 
CRTh2 mRNA levels at low concentration is similar to that seen with transcriptional 
regulation of Period circadian protein homolog (PER) [113]. The GR antagonist RU486 
inhibited this change in CRTh2 mRNA, which indicates GC mediated transcriptional 
regulation. Our lab has identified potential GREs on the CRTh2 locus using ENCODE data, 
in DNase hypersensitive sites that were uniquely present in the Th2 cells (Figure 4) [115]. 
Thus, direct GR regulation of CRTh2 is possible. This low concentration GC response of 
CRTh2 mRNA may indicate that another transcription factor interacts with the GR and is the 
transcription limiting protein. For example, the GR has been shown to interact with ERα and 
AP-1 [176]. The potential for GR and ERα interaction to regulate CRTh2 could be interesting 
and provide insight into the disproportionate representation of severe asthma among females 
[2].  
Using flow cytometry, surface expression of CRTh2 was assessed and typically showed ~20-
40% positivity. Interestingly, in CCRF-CEM cells surface expression in response to 
dexamethasone treatment did not reliably reflect the mRNA changes. This discrepancy may 
be associated with features particular to CCRF-CEM cells, an immortalized cancer T cell 
line. This was surprising, since the abundance of CRTh2 mRNA in these cells was quite high 
(Ct ~26). This could be due to the fact that this line grows particularly fast, doubling every 24 
hours, and may therefore be constantly shuttling CRTh2 to and from the surface. 
Alternatively, it is possible the CCRF-CEM cells may not have a robust representation of the 
machinery needed for membrane transport of CRTh2. For example, mast cells have been 
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shown to have intracellular expression of CRTh2 but little on the cell surface, presumably 
due to the lack of machinery [83]. CCRF-CEM cells may be like mast cells and lack 
sufficient amount of the proteins needed to transport CRTh2. Further work such as 
performing western blot analysis for total abundance of CRTh2 protein and/or intracellular 
CRTh2 staining should be done and could help us understand this discrepancy, 
To address the limitation in CCRF-CEM cells we chose to examine dexamethasone effects 
using more physiologically relevant in vitro differentiated Th2 cells. To determine whether 
the CRTh2 mRNA levels are reflected at the surface, we repeated these dexamethasone 
treatments using primary Th2 cells. I found that after 24 hours, 0.01-1μM dexamethasone 
treatment increased CRTh2 mRNA transcript levels in primary Th2 cells, to greater extent 
(4-fold) then CCRF-CEM cells (2-fold). The percentage of cells positive for CRTh2 and 
abundance of CRTh2 per cell was increased in response to 0.01μM treatment but not at 
higher concentrations. Interestingly, this was the lowest concentration of dexamethasone and 
yet was the only dose that had an effect on CRTh2 surface expression. Determining total 
CRTh2 protein with techniques such as a Western blot may indicate that total CRTh2 
changes reflect mRNA transcript changes. Since proteins involved in CRTh2 membrane 
transport have not been identified the effect GCs have on CRTh2 transport is unclear, but it is 
plausible that at high doses GCs may affect expression or activity of these proteins.  
The ability of GCs to increase CRTh2 transcription is novel and provides new insight into 
how GCs may regulate Th2 cells. However, these results are contradictory to the anti-
inflammatory effects of GCs, particularly the ability of GCs to inhibit type 2 cytokine 
production [121, 123]. Our finding of increased CRTh2, but inhibition of IL-13, could mean 
that at low concentration GC can mediate suppression of Th2 inflammation, but maintenance 
of Th2 cells. Specifically, with patients that have high level of Th2 cells in their airways or 
blood the low dose GC treatment could worsen the disease over time. If so, this could have 
significant clinical implications since the GC available in vivo is dependent on multiple 
factors such as amount prescribed, compliance as well as the individual’s GC metabolism. 
Therefore, getting the dose within the therapeutic range for suppression of inflammation is 
important, as lower amounts could contribute to GC-mediated persistence of Th2 cells. 
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4.2 GCs Induce Apoptosis in Th2 cells  
One of the major functions of GCs is the ability to induce apoptosis of T cells [177]. GCs 
mediate apoptosis by reducing the anti-apoptotic proteins BCL-2 and BCL-xL and activating 
caspases [141]. The ability of GCs to induce apoptosis is dependent on dose and exposure 
time, with different cell types varying in sensitivity [144]. To assess the ability of Th2 cells 
to regulate GC-induced apoptosis we needed to determine the dose and exposure time of GC 
needed to induce apoptosis.  
To determine this, we treated CCRF-CEM cells with dexamethasone and identified that 48 
hours (but not 24 hours) of high dose dexamethasone (1μM) treatment induced apoptosis. It 
is interesting to note that 1µM concentration also resulted in elevated CRTh2 mRNA 
transcript levels, suggesting that induction of apoptosis likely outweighs any potential pro-
inflammatory effect. However, dexamethasone concentrations up to 1μM exposed for 48 
hours were not able to induce apoptosis in primary Th2 cells. The GC resistance exhibited by 
primary Th2 cells were a result of the 5ng/mL of IL-2 used to culture the cells. Similar to 
PGD2-CRTh2 activation, IL-2 activates the AKT pathway which inhibits caspase-3 mediated 
apoptosis [171]. Previous studies by Xue et al. indicated that in the absence of IL-2, Th2 
cells undergo apoptosis [98]. Therefore, in order to assess apoptosis in primary Th2 cells we 
had to first determine the amount of IL-2 that will sustain the cells but will permit a GC 
response. We found 1.25ng of IL-2 permitted Th2 cells to become responsive to GC-induced 
apoptosis. At higher doses of GCs the apoptotic ability of GR may outweigh the level of IL-2 
present, again going back to the importance of sufficient amounts of GCs. This is relevant 
clinically because cells from severe asthmatics have been shown to produce high levels of 
IL-2 and have more Th2 cells relative to mild/moderate asthmatics [3, 30]. Thus, if severe 
asthmatic patients have more IL-2 this may reduce the Th2 cells response to GC.  
4.3 PGD2 Does Not Rescue Th2 cells From Glucocorticosteroid 
Induced Apoptosis 
PGD2 binding to CRTh2 has been shown to inhibit apoptosis induced by IL-2 starvation [98]. 
CRTh2 activates PI3K signaling pathway which leads to the inhibition of BAD and prevents 
BAD from interfering with anti-apoptotic BCL proteins (Figure 21) [98], while GCs can 
47 
 
 
downregulate BCL proteins to induce apoptosis. Therefore, these two pathways overlap and 
compete [142]. This is significant because PGD2 levels correlate with asthma severity, 
indicating patients with the highest level of Th2 cells have the highest levels of PGD2 [4]. If 
PGD2 can inhibit GC-induced apoptosis, then this may be a reason for Th2 cells to be 
sustained in circulation.  
To test this, we pre-treated CCRF-CEM cells with DK-PGD2 for 30 minutes in the presence 
and absence of 1μM dexamethasone. However, we found that DK-PGD2 did not inhibit GC-
induced apoptosis. We considered whether this was related to the CCRF-CEM cell line and 
whether these cells were unable to respond to PGD2 stimulation. To test this we assessed the 
ability of DK-PGD2 to drive type 2 cytokine expression [99]. Preliminary data from the lab 
shows that CCRF-CEM cells did not have detectable levels of IL-13 mRNA transcripts 
following PGD2 treatment (3, 6, 8 12, and 24 hours). CRTh2 is a GPCR, thus when activated 
results in calcium mobilization [95]. However, preliminary data of calcium flux, showed the 
absence of calcium mobilization following stimulation of CCRF-CEM cells with DK-PGD2. 
We also used the more potent agonist 15-R-Methyl PGD2 and found similar results. The 
reason for our inability to activate CRTh2 signaling is difficult to pinpoint and again may be 
related to using a leukemia cell line.  
To determine whether the lack of response from DK-PGD2 was a limitation of the cell line, 
we examined the effect of DK-PGD2 with Th2 cells cultured with 0 or 1.25 ng/mL of IL-2. 
We found that the percentage of Annexin V+ cells was not reduced with DK-PGD2 pre- 
treatment. However, there are many factors to consider with these experiments and we are 
still not confident in this negative result. Reducing the concentration of IL-2 renders Th2 
cells more responsive to GC-induced apoptosis, which may alter the optimal time to detect 
apoptotic effects. Indeed, after only 24 hours we observed a high proportion of apoptotic 
cells (40%) with 0ng of IL-2 (data not shown). Therefore, future experiments could reassess 
the ability of PGD2 to inhibit apoptosis at earlier time points. Secondly, the fact that IL-2 and 
PGD2 are both survival factors activating the PI3K/AKT pathway suggests that perhaps the 
lack of PGD2 effect may be related to growth factors in the media, though experiments 
completed with 0, 0.5 and 5% serum, showed no difference in the ability of DK-PGD2 to 
reduce apoptosis (preliminary data). Finally, it is important to recognize that Th2 cells 
express HPGDS, the enzyme that produces PGD2 [4]. For this reason, we considered the 
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possibility that endogenous PGD2 production was reducing the ability of Th2 cells to respond 
to exogenous PGD2. To test this, we performed a set of experiments where we cultured the 
cells in cyclooxygenase inhibitor, to inhibit PGD2 production (preliminary data). However, 
this too failed to alter the ability of PGD2 to inhibit GC-induced apoptosis or induce IL-13 
expression (data not shown). Another possibility is that these cells have upregulated proteins 
that inhibit CRTh2 signaling. For instance, β-arrestin has been shown to bind to the c-
terminal end of CRTh2 and inhibit its activity [178]. Ultimately, western blot co-
immunoprecipitation experiments are needed to assess CRTh2-β-arrestin interaction to 
confirm this possibility. If they do interact then we could utilize siRNA to knockdown β-
arrestin expression to confirm this recovers PGD2-CRTh2 signaling and then re-assess the 
effect PGD2 on GC-induced apoptosis.   
 
 
 
 
 
 
 
 
Figure 19: Regulation of Apoptosis in Th2 cells 
Th2 cell regulation of apoptosis involves different factors but all converge to anti-apoptotic 
BCL family proteins. Apoptosis induced by IL-2 starvation allows BAD to inhibit BCL 
proteins allowing for cytochrome C release from the mitochondria (1). GCs upregulates 
expression of GILZ which downregulates BCL proteins to induce apoptosis (2). Apoptosis 
can be inhibited by activation of CRTh2 (3) and IL-2 (4) through PI3K signaling which 
inhibits the BAD protein.   
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4.4 T Cell Activation Inhibits Glucocorticosteroid Signaling  
The effect of GCs on Th2 cells is important in both the resting and activation state. Th2 cells 
in vivo are activated by dendritic cells to elicit an inflammatory response to an allergen [44]. 
CD3 and CD28 engagement activates pro-inflammatory transcription factors such as NFAT, 
AP-1 and NFκB [158, 172]. Signaling pathways activated in T cells and pathways activated 
by GCs overlap and thus may interfere with each other. For instance, GR and AP-1 have 
been shown to demonstrate reciprocal inhibition [133].  
Therefore, to determine the effect of GCs on activated T cells, CCRF-CEM cells were treated 
with dexamethasone in the presence or absence of PMA and Ionomycin, chemicals that 
activate PKC and flux calcium, and therefore mimic CD3 and CD28 cross linking. We had 
seen that in primary Th2 cells GCs were able to reduce IL-13 mRNA transcript levels. 
CCRF-CEM cells do not have basal expression of IL-13 thus they had to be activated in 
order to produce cytokines. We wanted to assess whether T cell activation would inhibit the 
GR from reducing IL-13 mRNA levels. We found that after dexamethasone treatment IL-13 
mRNA levels were significantly reduced in activated T cells. However, there was only 30% 
reduction of IL-13 mRNA in activated cells compared to the 80% reduction seen in resting 
primary Th2 cells.  
To assess whether the blunted regulation of IL-13 by GCs was a result of reduced GR 
activity we treated CCRF-CEM cells with dexamethasone along with PMA and ionomycin. 
As expected, we found that FKBP5 mRNA transcript levels were increased in response to 
dexamethasone, but the effect was significantly less in activated cells. This phenomenon was 
similar with GR transcript levels, which were higher in resting cells in response to 
dexamethasone treatment compared to activated cells. These data suggest that activated Th2 
cells are less responsive to GC, due to downregulation of GR signaling genes. This is 
significant because regulation of FKBP5 and GR are essential for maintaining GR function. 
Reduction of FKBP5 and GR mRNA indicate that there could be a reduction in GR effect. 
This makes the IL-13 results more significant because even with reduced activity, the GR 
was still able to inhibit IL-13 mRNA expression. If GR activity is reduced we wanted to 
assess whether this would affect the dexamethasone-mediated upregulation of CRTh2. 
However we found that the downregulation of by T cell activation, could not be reversed by 
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dexamethasone treatment [80]. However, whether this is due to effects on CRTh2 
transcription rather than reduced GR activity, is possible. Work in our lab has identified that 
NFAT binds to the CRTh2 locus upon activation to downregulate mRNA. NFAT-AP-1 sites 
have been shown to overlap with GREs, thus preventing the GR from regulating transcription 
(Maclean, unpublished).  
Previous research has identified that GR signaling can interfere with factors up-regulated in 
T cell activation and vice versa [53, 172]. The level of T cell activation versus GR activation 
becomes important when trying to understand two competing pathways. With FKBP5 and 
GR levels reduced during T cell activation this indicates that the level of activation 
outweighs GR signaling. This again becomes evident with the inability of GR to regulate 
CRTh2 expression as previously described. Potentially, this points to the fact that GR 
resistance may occur from constant T cell activation which is a feature of chronic allergen 
exposure. Thus, low dose GCs in patients may not be able to surmount the level of allergen 
induced T cell activation, thereby rendering GCs ineffective.  
4.5 Conclusion 
The data demonstrate that the effect of GCs on Th2 cells is largely dose dependent. Whether 
cells are at rest or activated, to promote anti-inflammatory effects of the GR a competitive 
dose of GCs is necessary. Clinically, this may translate to prescribing more GCs since 
insufficient doses of GCs enhance the potential for Th2 mediated inflammation. Side effects 
from GCs are a concern, as long-term treatment can lead to developing cataracts, 
osteoporosis and adrenal insufficiency. Interestingly, this work suggests that there may be 
side effects from taking low doses that suppress cytokines but are insufficient to induce Th2 
cell apoptosis. Insufficient dose of GCs may allow Th2 cells to survive and thrive due to 
CRTh2 upregulation. The balance between GCs and Th2 inflammation forces us to rethink 
asthma therapy strategies based on patient characteristics (Figure 20). One approach of 
asthma therapy could be to measure the drop in Th2 cells as they undergo GC induced 
apoptosis. This approach should be coupled with improvements in GC selectivity and 
potency due to the side effects many patients experience when taking high doses of the 
currently available GCs. Collectively, this study highlights the importance of further work to 
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develop methods for determining a personalized approach for achieving maximum anti-
inflammatory effects.  
 
 
 
 
 
 
 
Figure 20: The effect of glucocorticosteroids is dose dependent 
Our data suggest that the ability of GCs to promote or reduce inflammation is dependent on 
dose of GCs. 1) The ability of GCs to increase CRTh2 expression and reduce IL-13 shows 
that GCs can inhibit immediate inflammatory effects while enhancing Th2 inflammatory 
potential. 2) High dose GCs induces apoptosis in Th2 cells and thereby reduce Th2 mediated 
inflammation. 3) Activation of T cells inhibits GC response and thereby shifts the balance 
towards increased inflammation.  
4.6 Future Direction 
GCs function is dependent on dose, which means the strength of GCs is important in 
determining the effect. To validate these findings, it would be interesting to compare GCs of 
different potencies with their ability to regulate transcription and apoptosis. This will be 
directly applicable clinically as although there are guidelines for prescribing doses of GCs, 
there are no current guidelines for which inhaled GCs to prescribe.  
For this study, we focused on CRTh2 surface expression rather than total protein expression 
because surface CRTh2 is the functional protein. One of the downfalls is that because we 
assessed surface expression we are still unclear whether mRNA changes at concentrations 
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above 0.01µM are reflected by total CRTh2 protein. Determining total protein will also help 
identify whether the limiting factor is the ability of cells to transport CRTh2 to the surface.  
One major limitation of this study is the lack of functional readout for the increase in CRTh2 
at low dose GCs. This increase could have implications in responses following allergen 
exposure leading to enhanced cytokines, chemotaxis and/or Th2 cell survival. Pre-treating 
Th2 cells with low dose GCs prior to PGD2 treatment may provide evidence of the 
deleterious effect of low dose GC.  
CRTh2 activation is considered to play a significant role in asthma pathogenesis. The 
obvious thought would be to inhibit PGD2 production to reduce inflammation. It may not be 
that simple since there is an asthma phenotype called aspirin sensitive asthma that is 
mediated primarily by leukotrienes [179]. Since arachidonic acid is a precursor for both 
PGD2 and leukotrienes [180], when aspirin inhibits the COX enzymes the production of 
PGD2 is reduced leading to increased production of leukotrienes [180]. Therefore, inhibition 
of PGD2 production may be an effective approach for reducing inflammation, but would have 
to be tested in patients that do not exhibit aspirin sensitivity.  
This study focuses on the balance between GC signaling and Th2 inflammation. Although 
severity of asthma has been correlated with PGD2 and percentage of Th2 cells, this does not 
address why severe asthmatics have elevated inflammation in the first place. This could be 
related to GC effect on Th2 cell differentiation. We have seen that GCs promote 
differentiation of Tregs, whether this holds true for Th2 cells remains to be seen. Previous 
research has shown that CD4+ T cells pretreated with GCs under differentiating conditions 
enhances type 2 cytokine release. Thus, although we have shown GCs can reduce type 2 
cytokines, GC treatment prior to the production of cytokines may help prime the cells for an 
enhanced cytokine release. This could further provide evidence of the effect of low dose GCs 
in not only sustaining but developing Th2 cells.  
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